Further analysis of the transcriptomic data and the anti–PD-1 therapy response in a cohort of 30 patients with metastatic melanoma (38) revealed that tumors with higher IL10RB-DT expression are resistant to anti–PD-1 treatment (Fig. 2F). The gene discussed is PDCD1; the disease is metastatic melanoma.